(Q33397349)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Jean-Philippe Spano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Vignot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

T De La Motte Rouge

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

L Hassani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

R Mouawad

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

F Menegaux

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

D Khayat

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

L Leenhardt

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

25 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1421-1428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

International patterns and trends in thyroid cancer incidence, 1973-2002

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

New therapeutic approaches for metastatic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Standard and emerging therapies for metastatic differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0070-2

Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study)

21 January 2018

1 reference

12 December 2020

First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study

1 reference

12 December 2020

1 reference

12 December 2020

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

1 reference

12 December 2020

Chemotherapy of thyroid carcinoma

1 reference

12 December 2020

Oxaliplatin: mechanism of action and antineoplastic activity

1 reference

12 December 2020

10.1007/S12032-011-0070-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21947747%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

1018919578

0 references

1 reference